These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3415204)

  • 21. Pharmacokinetics and pharmacodynamics of melphalan in isolated limb infusion for recurrent localized limb malignancy.
    Roberts MS; Wu ZY; Siebert GA; Anissimov YG; Thompson JF; Smithers BM
    Melanoma Res; 2001 Aug; 11(4):423-31. PubMed ID: 11479432
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Severe acute regional toxicity after normothermic or 'mild' hyperthermic isolated limb perfusion with melphalan for melanoma.
    Vrouenraets BC; Kroon BB; Klaase JM; Nieweg OE; van Slooten GW; van Dongen JA
    Melanoma Res; 1995 Dec; 5(6):425-31. PubMed ID: 8589617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Status of the blood after perfusion with various doses of chemopreparations and the efficiency of an artificial ciruclation device in malignant tumors of the extremities].
    Antelava NV; Trapeznikov NN; Iavorskiĭ VV; Amcheslavskiĭ EG
    Vestn Khir Im I I Grek; 1968 Aug; 101(8):31-5. PubMed ID: 4973965
    [No Abstract]   [Full Text] [Related]  

  • 24. Lucy Wortham James lecture. Regional perfusion. Current sophistication, what next?
    Krementz ET
    Cancer; 1986 Feb; 57(3):416-32. PubMed ID: 3080216
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Anti-blastic hyperthermic perfusion in the treatment of melanoma of the extremities in the loco-regional diffusion phase].
    Di Filippo F; Garinei R; Anzà M; Cavaliere F; Botti C; Perri P; Di Filippo S
    Tumori; 2003; 89(4 Suppl):241-3. PubMed ID: 12903606
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study.
    Olieman AF; Liénard D; Eggermont AM; Kroon BB; Lejeune FJ; Hoekstra HJ; Koops HS
    Arch Surg; 1999 Mar; 134(3):303-7. PubMed ID: 10088573
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Results of regional isolation perfusion with cytostatics in patients with soft tissue tumors of the extremities.
    Klaase JM; Kroon BB; Benckhuijsen C; van Geel AN; Albus-Lutter CE; Wieberdink J
    Cancer; 1989 Aug; 64(3):616-21. PubMed ID: 2743257
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TNF-alpha and melphalan-based isolated limb perfusion: no evidence supporting the early destruction of tumour vasculature.
    Podleska LE; Funk K; Umutlu L; Grabellus F; Taeger G; de Groot H
    Br J Cancer; 2015 Aug; 113(4):645-52. PubMed ID: 26171939
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Limb desmoid tumors: a possible role for isolated limb perfusion with tumor necrosis factor-alpha and melphalan.
    Lev-Chelouche D; Abu-Abeid S; Nakache R; Issakov J; Kollander Y; Merimsky O; Meller I; Klausner JM; Gutman M
    Surgery; 1999 Nov; 126(5):963-7. PubMed ID: 10568198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Balloon catheter hypoxic abdominal and pelvic perfusion with tumour necrosis factor-alpha, Melphalan and Mitomycin C: a pharmacokinetic study in pigs.
    van IJken MG; de Bruijn EA; ten Hagen TL; de Boeck G; van Eijck CH; Eggermont AM
    Eur J Surg Oncol; 2004 Aug; 30(6):699-707. PubMed ID: 15256247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A clinical and pharmacokinetic study of isolated limb perfusion with heat and melphalan for melanoma.
    Minor DR; Allen RE; Alberts D; Peng YM; Tardelli G; Hutchinson J
    Cancer; 1985 Jun; 55(11):2638-44. PubMed ID: 3995475
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of hyperthermic isolated limb perfusion with recombinant tumor necrosis factor alpha and melphalan on the human fibrinolytic system.
    Zwaveling JH; Maring JK; Mulder AB; Bom VJ; van Ginkel RJ; Schraffordt Koops H; Girbes AR; Hoekstra HJ; van der Meer J
    Cancer Res; 1996 Sep; 56(17):3948-53. PubMed ID: 8752162
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isolated limb perfusion and isolated limb infusion for malignant lesions of the extremities.
    Sanki A; Kroon HM; Kam PC; Thompson JF
    Curr Probl Surg; 2011 Jun; 48(6):371-430. PubMed ID: 21549235
    [No Abstract]   [Full Text] [Related]  

  • 34. Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb.
    Rauschecker HF; Foth H; Michaelis HC; Horst F; Gatzemeier W; Willenbrock C; Voth E; Kahl GF
    Cancer Chemother Pharmacol; 1991; 27(5):379-84. PubMed ID: 1998997
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Regional hyperthermic perfusion with cytostatic agents in malignant melanoma of the extremities (author's transl)].
    Ghussen F; Nagel K; Groth W
    Dtsch Med Wochenschr; 1981 Nov; 106(48):1612-5. PubMed ID: 7308000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hyperthermic isolated limb perfusion with tumour necrosis factor and melphalan as treatment of locally advanced or recurrent soft tissue sarcomas of the extremities.
    Schraffordt Koops H; Eggermont AM; Liènard D; Kroon BB; Hoekstra HJ; van Geel AN; Nieweg OE; Lejeune FJ
    Radiother Oncol; 1998 Jul; 48(1):1-4. PubMed ID: 9756165
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isolated limb perfusion for melanoma: effectiveness and toxicity of cisplatin compared with that of melphalan and other drugs.
    Thompson JF; Gianoutsos MP
    World J Surg; 1992; 16(2):227-33. PubMed ID: 1561803
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The role of isolated limb perfusion for melanoma confined to the extremities.
    Eggermont AM; van Geel AN; de Wilt JH; ten Hagen TL
    Surg Clin North Am; 2003 Apr; 83(2):371-84, ix. PubMed ID: 12744614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dosimetry of cytostatics in hyperthermic regional isolated perfusion.
    van Os J; Schraffordt Koops H; Oldhoff J
    Cancer; 1985 Feb; 55(4):698-701. PubMed ID: 3967166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Renal function in cancer patients treated with hyperthermic isolated limb perfusion with recombinant tumor necrosis factor-alpha and melphalan.
    Zwaveling JH; Hoekstra HJ; Maring JK; v Ginkel RJ; Schraffordt Koops H; Smit AJ; Girbes AR
    Nephron; 1997; 76(2):146-52. PubMed ID: 9200405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.